|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents: | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing balances with banks | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Investment securities available-for-sale | ||||||||||||||||||||
| Equity securities | ||||||||||||||||||||
| Loans held-for-sale | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Equity method investments | ||||||||||||||||||||
| Assets held-for-sale | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Accrued interest receivable and other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| FHLB and other borrowings | ||||||||||||||||||||
| Subordinated debt | ||||||||||||||||||||
| Senior term loan | ||||||||||||||||||||
| Liabilities held-for-sale | ||||||||||||||||||||
| Revolving line of credit | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Common stock - par value $1; 40,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 14,322,668 and 12,947,151 shares issued and outstanding, respectively, as of June 30, 2026 and 14,042,683 and 12,715,598 shares issued and outstanding, respectively, as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock - 1,375,517 and 1,327,085 shares at cost as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Total equity attributable to parent | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
Loading...
